Production and purification of a recombinant staphylococcal enterotoxin B vaccine candidate expressed in Escherichia coli

Protein Expression and Purification

Volumn 24, Issue 2, 2002, Pages 302-312

  Coffman, J Daniel ^a   Zhu, Jianwei ^a   Roach, John M ^a   Bavari, Sina ^b   Ulrich, Robert G ^b   Giardina, Steven L ^a  

^a SAIC FREDERICK INC   (United States)

^b Dept of Immunol and Molec Biology Bldg 1425 U States Army Med R   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI; STAPHYLOCOCCUS;

BACTERIAL ANTIGEN; ENTEROTOXIN; RECOMBINANT PROTEIN; STAPHYLOCOCCUS ENTEROTOXIN B; STAPHYLOCOCCUS VACCINE;

ARTICLE; BIOSYNTHESIS; CHROMATOGRAPHY; ESCHERICHIA COLI; IMMUNOLOGY; ISOLATION AND PURIFICATION; SITE DIRECTED MUTAGENESIS;

ANTIGENS, BACTERIAL; CHROMATOGRAPHY; ENTEROTOXINS; ESCHERICHIA COLI; MUTAGENESIS, SITE-DIRECTED; RECOMBINANT PROTEINS; STAPHYLOCOCCAL VACCINES;

EID: 0036511659     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1006/prep.2001.1556     Document Type: Article

References (28)

1. Ulrich, R. G., Olson, M. A., and Bavari, S. (1998) Development of engineered vaccines effective against structurally related bacterial superantigens. Vaccine 16, 1857-1864.
2. Ulrich, R. G., Bavari, S., and Olson, M. A. (1995) Bacterial superantigens in human disease: Structure, function, and diversity. Trends Microbiol. 3, 463-468.
3. Ulrich, R. G. (2000) Evolving superantigens of Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 27, 1-7.
4. Swaminathan, S., Furey, W., Pletcher, J., and Sax, M. (1992) Crystal structure of staphylococcal enterotoxin B, a superantigen. Nature 359, 801-806.
5. Bavari, S., Ulrich, R. G., and LeClaire, R. D. (1999) Cross-reactive antibodies prevent the lethal effects of Staphylococcus aureus superantigens. J. Infect. Dis. 180, 1365-1369.
6. Liljeqvist, S., and Stahl, S. (1999) Production of recombinant subunit vaccines: Protein immunogens, live delivery systems and nucleic acid vaccines. J. Biotechnol. 73, 1-33.
7. Warren, J. R., Spero, L., and Metzger, J. F. (1973) Antigenicity of formaldehyde inactivated staphylococcal enterotoxin B. J. Immunol. 111, 885-892.
8. Wood, A. C., Chadwick, J. S., Brehm, R. S., Todd, J., Arbuthnott, J. P., and Tranter, H. S. (1997) Identification of antigenic sites on staphylococcal enterotoxin B and toxoid. FEMS Immunol. Med. Microbiol. 17, 1-10.
9. Bavari, S., Dyas, B., and Ulrich, R. G. (1996) Superantigen vaccines: A comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A. J. Infect. Dis. 174, 338-345.
10. Ulrich, R. G., Bavari, S., and Olson, M. A. (1995) Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules. Nat. Struct. Biol. 2, 554-560.
11. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
12. Friehs, K., and Reardon, K. F. (1993) Parameters influencing the productivity of recombinant E. coli cultivations. Adv. Biochem. Eng. Biotechnol. 48, 55-74.
13. Hannig, G., and Makrides, S. C. (1998) Strategies for optimizing heterologous protein expression in Escherichia coli. Trends Biotechnol. 16, 54-60.
14. Moore, J. T., Uppal, A., Maley, F., and Maley, G. F. (1993) Overcoming inclusion body formation in a high-level expression system. Protein Expression Purif. 4, 160-163.
15. Studier, F. W., and Moffatt, B. (1986) Use of bacteriophage T7 RNA polymerase to direct selective high-level expression of cloned genes. J. Mol. Biol. 189, 113-130.
16. Makrides, S. C. (1996) Strategies for achieving high-level expression of genes in Escherichia coli. Microbiol. Rev. 60, 512-538.
17. Schutte, H., and Kula, M.-R. (1990) Pilot and process-scale techniques for cell disruption. Biotechnol. Appl. Biochem. 12, 599-620.
18. Van Reis, R., Goodrich, E. M., Yson, C. L., Frautschy, L. N., Dzengeleski, S., and Lutz, H. (1997) Linear scale ultrafiltration. Biotechnol. Bioeng. 55, 737-746.
19. Bailey, S. M., and Meagher, M. M. (1997) Crossflow microfiltration of recombinant Escherichia coli lysates after high pressure homogenization. Biotechnol. Bioeng. 56, 304-310.
20. Forman, S. M., DeBernardez, E. R., Feldberg, R. S., and Swartz, R. W. (1990) Crossflow filtration for the separation of inclusion bodies from soluble proteins in recombinant Escherichia coli cell lysate. J. Membr. Sci. 48, 263-279.
21. PDA Biotechnology Task Force on Purification and Scale-Up. (1992) Industry perspective on the validation of column-based separation processes for the purification of proteins. J. Parenter. Sci. Technol. May/June, 4687-4697.[Technical Rep. No. 14]
22. Jungbauer, A., and Boschetti, E. (1994) Manufacture of recombinant proteins with safe and validated chromatographic sorbents. J. Chromatogr. B 662, 143-179.
23. Manning, M. C., Patel, K., and Borchardt, R. T. (1989) Stability of protein pharmaceuticals. Pharm. Res. 6, 903-918.
24. Wang, W. (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185, 129-188.
25. U.S. Code of Federal Regulations. (1998) Title 21, Parts 210, 211 and 600. The National Archives and Records Administration Office of the Federal Register, Gov. Printing Office, Washington, DC.
26. Guidance for industry, content and format of chemistry, manufacturing and controls information and establishment description information for a vaccine or related product. (1999) Office of Communication, Training and Manufacturers Assistance, U.S. Department of Health and Human Services, FDA-CBER, Rockville, MD.
27. Zabriskie, D. (1998) Strengthening the biological weapons convention and implications on the pharmaceutical and biotechnology industry. Curr. Opin. Biotechnol. 9, 312-318.
28. Ferguson, J. R. (1997) Biological weapons and U.S. law. JAMA 278, 357-360.